Vaccines News and Research RSS Feed - Vaccines News and Research

Volatile anesthetics may combat viral and bacterial infections in the lung

Volatile anesthetics may combat viral and bacterial infections in the lung

In use for more than a century, inhaled anesthetics like nitrous oxide and halothane have made modern surgery possible. Now, in experiments in mice, researchers at Johns Hopkins and elsewhere have added to evidence that certain so-called "volatile" anesthetics -- commonly used during surgeries -- may also possess powerful effects on the immune system that can combat viral and bacterial infections in the lung, including influenza and pneumonia. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942. [More]
Vaccine exemption levels low, vaccination rates high in U.S.

Vaccine exemption levels low, vaccination rates high in U.S.

Vaccine exemption levels for kindergarteners are low for most states and infant vaccination rates are high nationally, according to data from two reports published in this week's Morbidity and Mortality Weekly Report. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

The American Gastroenterological Association, in partnership with the Crohn's & Colitis Foundation of America and Janssen Biotech, Inc., announced today that Theresa Alenghat, VMD, PhD, from Cincinnati Children's Hospital Medical Center, OH, was awarded with the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research. [More]
New research could potentially yield novel platform for cancer vaccines

New research could potentially yield novel platform for cancer vaccines

New research led by Wyss Core Faculty member David Mooney, Ph.D., in collaboration with researchers at the Dana-Farber Cancer Institute could potentially yield a new platform for cancer vaccines. Leveraging a biologically inspired sponge-like gel called "cryogel" as an injectable biomaterial, the vaccine delivers patient-specific tumor cells together with immune-stimulating biomolecules to enhance the body's attack againstcancer. [More]
Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Individuals who received the flu vaccine were protected for up to 6 months post-vaccination, the duration of most flu seasons, according to a study presented at the 2015 International Conference on Emerging Infectious Diseases. [More]
New study affirms value of influenza vaccination among older people

New study affirms value of influenza vaccination among older people

A new study of the records of millions of nursing home residents affirms the value of influenza vaccination among the elderly. The Brown University analysis found that between 2000 and 2009, the better matched the vaccine was for the influenza strain going around, the fewer nursing home residents died or were hospitalized. [More]
NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. [More]
Study sheds light on helper cells and killer cells

Study sheds light on helper cells and killer cells

Scientists at the University of Bonn, together with colleagues from the USA and Japan, have shed light on an important immune mechanism. Their work shows how the body provides the important killer cells with a helper in the case of an infection. The study could point the way to better vaccines in the future. [More]
Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
60P to commence Phase II clinical trial among dengue fever patients

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients. [More]

CRY launches fundraising and awareness campaign 'Healthy Start'

In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change. [More]
H1N1 vaccine developed at UNMC to be evaluated in animal study

H1N1 vaccine developed at UNMC to be evaluated in animal study

An H1N1 vaccine developed at the University of Nebraska Medical Center will enter a definitive round of testing this month, and researchers hope to establish its ability to ward off the virus. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
New book from the March of Dimes details successful program to reduce preterm birth

New book from the March of Dimes details successful program to reduce preterm birth

Details of a program that successfully reduced preterm birth are available for health care professionals in a new book from the March of Dimes. [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
Applying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi

Applying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi

Communications professionals often are expected to be experts in all facets of the vast spectrum of communications, from brand, corporate, crisis and digital communications to corporate reputation and channel strategy and everything in between. [More]
Immunization programmes face a growing challenge from vaccine hesitancy

Immunization programmes face a growing challenge from vaccine hesitancy

People who delay or refuse vaccines for themselves or their children are presenting a growing challenge for countries seeking to close the immunization gap. Globally, one in 5 children still do not receive routine life-saving immunizations, and an estimated 1.5 million children still die each year of diseases that could be prevented by vaccines that already exist, according to the World Health Organization. [More]
Advertisement
Advertisement